Accretion Pharmaceuticals Announces Corporate Office Relocation of RTA KFin Technologies
Accretion Pharmaceuticals Ltd 路 Others (Uncategorized) 路 16 Nov 2026, 10:33 pm
Accretion Pharmaceuticals Announces Corporate Office Relocation of RTA KFin Technologies Accretion Pharmaceuticals Limited announced that its Registrar and Share Transfer Agent, KFin Technologies Limited, will relocate its Corporate Office to Rajapushpa West Avenue, Kokapet, Hyderabad effective 1st Dec'26. All future correspondence, notices, and documents intended for the RTA's Corporate Office must be directed to the new address. The Registered Office of KFin Technologies remains unchanged.
Original exchange filing (PDF)
More announcements from Accretion Pharmaceuticals Ltd
- Accretion Pharmaceuticals Limited has informed the Exchange about Investor Presentation 路 03 Nov 2026
- Accretion Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 02 Nov 2026
- Accretion Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 31, 2026, titled "Company Reports 25.83% Revenue Growth and 72.63% PAT Growth in H1 FY27 and Strong EBITDA Growth of 72.28%; EBITDA Margin Improves to 22.48%". 路 31 Oct 2026
- Accretion Pharmaceuticals Limited has submitted to the Exchange, the unaudited financial results for the half year ended September 30, 2026. 路 31 Oct 2026
- Accretion Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 31-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 31 Oct 2026
- To consider and approve the financial results for the period ended September 30, 2026 路 31 Oct 2026
- Accretion Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Postal Ballot. Further, the company has submitted the Exchange a copy of Srutinizers report. 路 12 Oct 2026
- Accretion Pharmaceuticals Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company. 路 11 Oct 2026
